« back to Press Releases

February 28, 2018

AgeneBio Founder Michela Gallagher to Speak at 2018 NIH Alzheimer’s Research Summit

Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief Scientific Officer, HOPE4MCI Principal Investigator, and Krieger-Eisenhower Professor of Psychological and Brain Sciences at Johns Hopkins University, Michela Gallagher, PhD, will speak at the 2018 NIH Alzheimer’s Research Summit. The summit, a key strategic planning meeting tied to the implementation of the first goal of the National Plan to Address Alzheimer’s: to treat and prevent Alzheimer’s disease by 2025, will be held March 1-2 in Bethesda, MD. Dr. Gallagher will participate in the “Emerging Therapeutics” session to discuss AgeneBio’s programs targeting hippocampal hyperactivity in the mild cognitive impairment phase of prodromal Alzheimer’s disease on March 2.

Dr. Gallagher will discuss AgeneBio’s Phase 3 HOPE4MCI clinical trial for AGB101. AGB101 is the first and only therapeutic for mild cognitive impairment due to Alzheimer’s disease (MCI due to AD) targeting brain network imbalance and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. MCI due to AD is an intermediate stage between normal cognition and Alzheimer’s dementia in which memory and cognitive abilities are markedly worse than expected for a person’s age.

About AgeneBio

AgeneBio, Inc., is a development-stage CNS biopharmaceutical company developing innovative therapeutics aimed at preserving and restoring brain function for unserved patients afflicted with neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of mild cognitive impairment due to Alzheimer’s disease (MCI due to AD), the symptomatic pre-dementia stage of Alzheimer’s disease. If approved, AgeneBio’s Phase 3-ready lead candidate AGB101 will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s dementia. AgeneBio also has a novel GABA_A a5 small molecule program in discovery stage lead optimization with therapeutic potential for a spectrum of untreated conditions including MCI due to AD, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Media Contact
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com